[{"id":"27751dcd-f28f-4f36-b8db-e4042ae9fc77","acronym":"CVL006-T1002","url":"https://clinicaltrials.gov/study/NCT07157956","created_at":"2025-09-13T08:47:52.158Z","updated_at":"2025-09-13T08:47:52.158Z","phase":"Phase 1/2","brief_title":"CVL006 Combination Therapy in Advanced Solid Tumors","source_id_and_acronym":"NCT07157956 - CVL006-T1002","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 08/12/2028","primary_completion_date":" 08/12/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-09-05"},{"id":"cef8e42f-da33-450a-942c-ff0f7c445fa9","acronym":"PlugIN","url":"https://clinicaltrials.gov/study/NCT06906822","created_at":"2025-06-28T13:38:14.863Z","updated_at":"2025-06-28T13:38:14.863Z","phase":"Phase 2","brief_title":"PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients","source_id_and_acronym":"NCT06906822 - PlugIN","lead_sponsor":"Grupo Español Multidisciplinar de Melanoma","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-06-27"},{"id":"9c7ac936-fde1-4b07-9296-dad7240ad183","acronym":"","url":"https://clinicaltrials.gov/study/NCT04963153","created_at":"2021-07-15T13:06:11.818Z","updated_at":"2025-02-25T12:28:14.832Z","phase":"Phase 1","brief_title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","source_id_and_acronym":"NCT04963153","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR2 • NECTIN4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • FGFR2 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2022","start_date":" 07/07/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-24"},{"id":"e26feb64-5ce0-4689-b638-098d6bd0300f","acronym":"E-VIRTUE","url":"https://clinicaltrials.gov/study/NCT06041503","created_at":"2025-02-25T12:29:47.446Z","updated_at":"2025-02-25T12:29:47.446Z","phase":"Phase 2","brief_title":"Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)","source_id_and_acronym":"NCT06041503 - E-VIRTUE","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-24"},{"id":"99f591b9-7e23-4ea7-a5a0-fe1e2287e1db","acronym":"KEYNOTE-F21","url":"https://clinicaltrials.gov/study/NCT04225117","created_at":"2021-01-18T20:34:06.535Z","updated_at":"2025-02-25T15:18:27.870Z","phase":"Phase 2","brief_title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","source_id_and_acronym":"NCT04225117 - KEYNOTE-F21","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" BRAF • ER • ALK • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive","tags":["BRAF • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 329","initiation":"Initiation: 03/09/2020","start_date":" 03/09/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-12"},{"id":"38d14a85-f7dd-4762-9bf5-4da0e8be0e8f","acronym":"KEYMAKER-U04 Substudy","url":"https://clinicaltrials.gov/study/NCT05845814","created_at":"2023-05-06T15:04:43.804Z","updated_at":"2025-02-25T15:28:00.798Z","phase":"Phase 1/2","brief_title":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","source_id_and_acronym":"NCT05845814 - KEYMAKER-U04 Substudy","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 06/23/2023","start_date":" 06/23/2023","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-02-10"},{"id":"fcc72bbe-b0e5-47c6-94e9-7a67723d96e9","acronym":"KEYNOTE-905","url":"https://clinicaltrials.gov/study/NCT03924895","created_at":"2021-01-18T19:18:27.873Z","updated_at":"2025-02-25T15:26:04.852Z","phase":"Phase 3","brief_title":"Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)","source_id_and_acronym":"NCT03924895 - KEYNOTE-905","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 595","initiation":"Initiation: 07/24/2019","start_date":" 07/24/2019","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 12/15/2027","study_completion_date":" 12/15/2027","last_update_posted":"2025-01-29"},{"id":"db660b09-0f52-4a82-9f38-79007e8d5211","acronym":"MORPHEUS mUC","url":"https://clinicaltrials.gov/study/NCT03869190","created_at":"2021-01-18T19:04:50.965Z","updated_at":"2025-02-25T13:18:52.965Z","phase":"Phase 1/2","brief_title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","source_id_and_acronym":"NCT03869190 - MORPHEUS mUC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • gemcitabine • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • RG7827 • lomvastomig (RG7769)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 05/21/2026","study_completion_date":" 05/21/2026","last_update_posted":"2025-01-03"},{"id":"7bb8b08e-5d1b-431b-b5ae-8689cf85f453","acronym":"","url":"https://clinicaltrials.gov/study/NCT05656235","created_at":"2024-01-16T22:19:54.900Z","updated_at":"2025-02-25T15:36:00.703Z","phase":"Phase 2","brief_title":"Renal Retention in High Grade Upper Tract Urothelial Cancer","source_id_and_acronym":"NCT05656235","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/25/2024","start_date":" 11/25/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-12-11"},{"id":"f475956b-3e47-43de-9a86-08ae99dd5415","acronym":"","url":"https://clinicaltrials.gov/study/NCT05868265","created_at":"2023-05-22T16:05:30.447Z","updated_at":"2025-02-25T15:36:15.222Z","phase":"Phase 2","brief_title":"A Study of Enfortumab Vedotin in People with Urothelial Carcinoma of the Upper Urinary Tract","source_id_and_acronym":"NCT05868265","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-10-28"},{"id":"cbf742e9-f1eb-4f57-aeba-ca0937f853ae","acronym":"KEYNOTE-A39","url":"https://clinicaltrials.gov/study/NCT04223856","created_at":"2021-01-18T20:33:23.610Z","updated_at":"2025-02-25T16:09:50.347Z","phase":"Phase 3","brief_title":"Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer","source_id_and_acronym":"NCT04223856 - KEYNOTE-A39","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 886","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 08/08/2023","primary_completion_date":" 08/08/2023","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-09-27"},{"id":"0fac7b47-27bf-4bc6-a3e6-bbc5a58a9393","acronym":"NEPTUNE","url":"https://clinicaltrials.gov/study/NCT06356155","created_at":"2024-04-10T18:42:37.490Z","updated_at":"2024-07-02T16:35:10.234Z","phase":"Phase 2","brief_title":"Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer","source_id_and_acronym":"NCT06356155 - NEPTUNE","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-04-10"},{"id":"f8bd5c27-03e2-4692-9f60-a75a628609a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01409135","created_at":"2021-01-19T04:30:18.499Z","updated_at":"2024-07-02T16:35:15.277Z","phase":"Phase 1","brief_title":"A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4","source_id_and_acronym":"NCT01409135","lead_sponsor":"Astellas Pharma Inc","biomarkers":" NECTIN4","pipe":" | ","alterations":" NECTIN4 expression","tags":["NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 07/11/2011","start_date":" 07/11/2011","primary_txt":" Primary completion: 04/27/2015","primary_completion_date":" 04/27/2015","study_txt":" Completion: 04/27/2015","study_completion_date":" 04/27/2015","last_update_posted":"2024-03-12"},{"id":"e1c7608c-7f2d-486a-b5af-4dd6bb37d415","acronym":"ASG-22CE-13-2","url":"https://clinicaltrials.gov/study/NCT02091999","created_at":"2021-01-19T08:19:26.317Z","updated_at":"2024-07-02T16:35:22.622Z","phase":"Phase 1","brief_title":"A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4","source_id_and_acronym":"NCT02091999 - ASG-22CE-13-2","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" NECTIN4","pipe":" | ","alterations":" NECTIN4 expression","tags":["NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 05/14/2014","start_date":" 05/14/2014","primary_txt":" Primary completion: 12/07/2022","primary_completion_date":" 12/07/2022","study_txt":" Completion: 12/07/2022","study_completion_date":" 12/07/2022","last_update_posted":"2024-01-23"},{"id":"89cd4b3b-c7af-4bc4-a807-271c34e68ac3","acronym":"DAD","url":"https://clinicaltrials.gov/study/NCT04724018","created_at":"2021-01-26T15:52:12.079Z","updated_at":"2024-07-02T16:35:30.169Z","phase":"Phase 1","brief_title":"Sacituzumab Govitecan Plus EV in Metastatic UC","source_id_and_acronym":"NCT04724018 - DAD","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-11-07"},{"id":"e7196839-82de-487e-9e48-5e2293232085","acronym":"EV-201","url":"https://clinicaltrials.gov/study/NCT03219333","created_at":"2021-01-18T15:53:16.142Z","updated_at":"2024-07-02T16:35:35.420Z","phase":"Phase 2","brief_title":"A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer","source_id_and_acronym":"NCT03219333 - EV-201","lead_sponsor":"Astellas Pharma Inc","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Completed","enrollment":" Enrollment 219","initiation":"Initiation: 10/08/2017","start_date":" 10/08/2017","primary_txt":" Primary completion: 10/27/2020","primary_completion_date":" 10/27/2020","study_txt":" Completion: 07/28/2023","study_completion_date":" 07/28/2023","last_update_posted":"2023-09-28"},{"id":"16dce5e2-114a-457b-bc84-5e8804649d57","acronym":"","url":"https://clinicaltrials.gov/study/NCT04878029","created_at":"2021-05-07T11:52:57.724Z","updated_at":"2024-07-02T16:35:39.938Z","phase":"Phase 1","brief_title":"Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer","source_id_and_acronym":"NCT04878029","lead_sponsor":"Emory University","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/23/2021","start_date":" 07/23/2021","primary_txt":" Primary completion: 01/21/2025","primary_completion_date":" 01/21/2025","study_txt":" Completion: 01/21/2025","study_completion_date":" 01/21/2025","last_update_posted":"2023-08-15"},{"id":"13608c35-003d-49d5-8068-aba26867f816","acronym":"","url":"https://clinicaltrials.gov/study/NCT03070990","created_at":"2021-03-08T17:01:27.042Z","updated_at":"2024-07-02T16:36:49.222Z","phase":"Phase 1","brief_title":"A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma","source_id_and_acronym":"NCT03070990","lead_sponsor":"Astellas Pharma Inc","biomarkers":" NECTIN4","pipe":" | ","alterations":" NECTIN4 expression","tags":["NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/24/2017","start_date":" 04/24/2017","primary_txt":" Primary completion: 02/25/2019","primary_completion_date":" 02/25/2019","study_txt":" Completion: 02/25/2019","study_completion_date":" 02/25/2019","last_update_posted":"2020-03-04"},{"id":"d13a8f55-cafb-46da-97da-3d3cf4b8ee14","acronym":"","url":"https://clinicaltrials.gov/study/NCT04136808","created_at":"2021-01-18T20:15:22.365Z","updated_at":"2024-07-02T16:36:51.386Z","phase":"","brief_title":"An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma","source_id_and_acronym":"NCT04136808","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-01-13"}]